Brief: Oncopeptides: EC Approves Label Expansion Of Pepastxi To Third-Line Multiple Myeloma Treatment
09/11/2026 12:03
BRIEF-Oncopeptides: EC Approves Label Expansion Of Pepastxi To Third-Line Multiple Myeloma Treatment Nov 9 (Reuters) - Oncopeptides AB ONCO.ST:
EC APPROVES LABEL EXPANSION OF PEPASTXI TO THIRD-LINE MULTIPLE MYELOMA TREATMENT
Source text: ID:nMFNbmGgsL
Further company coverage: ONCO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Oncopeptides AB
See all newsBrief: Oncopeptides: EC Approves Label Expansion Of Pepastxi To Third-Line Multiple Myeloma Treatment
Sweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study